Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Proof of Principle Program - Phase I

Université Laval

$160,000.00

Optimization and Validation of Highly Cytocidal Substituted Phenyl Imidazolidin-2-one as Antimicrotubule Agents for Cancer Chemotherapy

FY 2010-11

Summary
In the past few years, we have discovered and developed two new families of potent anticancer molecules. The first group of drugs is active on most cancer cells such as breast, colon and skin cancers and could be useful for their treatment either alone or in combination with other drugs. The second group of compounds shows selectivity towards human breast cancer cells that often disseminate in the women body. These cells when disseminating form the so-called metastases and are very difficult to treat using the current chemotherapy. In that context, the new drugs are of particular interest since they could be used in combination with currently used medications to postpone or to abrogate the progression of the cancer and the formation of metastases. In this proposal, we will assess the anticancer activity of both families of drugs in mice bearing human cancer tumors such as colon or skin cancers. Specific experiments will be conducted to assess the efficacy of the drugs showing selectivity towards human breast cells on mice bearing human breast tumors. Our short-term objective is to confirm the potential of these compounds as anticancer drugs and our mid-term-objective is to interest industrial partners to help for bringing these molecules in clinical trials.
Program
Proof of Principle Program - Phase I
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
227974
Name
C.-Gaudreault René
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Proof of Principle
Projecttitle
Optimization and Validation of Highly Cytocidal Substituted Phenyl Imidazolidin-2-one as Antimicrotubule Agents for Cancer Chemotherapy
Programtype2
Operating Grants
Orgnameinp2
Université Laval
Cihramount2
$160,000
Cihrequipment2
$0
Programname2
Proof of Principle Program - Phase I
Keyworddelim
Anticancer Drug; Cancer; Drug Evaluation; Medicinal Chemistry
Abstract
In the past few years, we have discovered and developed two new families of potent anticancer molecules. The first group of drugs is active on most cancer cells such as breast, colon and skin cancers and could be useful for their treatment either alone or in combination with other drugs. The second group of compounds shows selectivity towards human breast cancer cells that often disseminate in the women body. These cells when disseminating form the so-called metastases and are very difficult to treat using the current chemotherapy. In that context, the new drugs are of particular interest since they could be used in combination with currently used medications to postpone or to abrogate the progression of the cancer and the formation of metastases. In this proposal, we will assess the anticancer activity of both families of drugs in mice bearing human cancer tumors such as colon or skin cancers. Specific experiments will be conducted to assess the efficacy of the drugs showing selectivity towards human breast cells on mice bearing human breast tumors. Our short-term objective is to confirm the potential of these compounds as anticancer drugs and our mid-term-objective is to interest industrial partners to help for bringing these molecules in clinical trials.
Competitiondate
201102
Approvedterm2
1 yr 0 mth
Pinamesdelim
C.-Gaudreault, René
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $160,000~ $0~
Université Laval - $160,000 Grant (2010-11) | Canada Spends